Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

Continuous intravenous epoprostenol improves exercise capacity, haemodynamics, and survival in severe primary pulmonary hypertension. Pulmonary hypertension can also be life-threatening in patients with connective tissue diseases. In a prospective open monocentre uncontrolled study, the effects of epoprostenol were evaluated in patients with severe pulmonary hypertension secondary to connective tissue diseases who were unresponsive to oral vasodilators (including calcium channel blockers) and continued to be in the New York Heart Association (NYHA) functional class III or IV despite conventional medical therapy. Seventeen patients received epoprostenol administered by a portable infusion pump associated with conventional therapy (oral anticoagulants, diuretics, supplemental oxygen). During the first six weeks of therapy, two (12%) patients died, of pulmonary oedema (n = 1) and severe sepsis (n = 1). In the fifteen remaining subjects, clinical and haemodynamic parameters improved significantly at six weeks. These patients were subsequently monitored for 80+/-48 (range 14-154) weeks after initiation of epoprostenol. Five (33%) patients died, of right heart failure (n = 2), severe sepsis (n = 2) or syncope (n = 1) and two patients were successfully transplanted 24 and 52 weeks after initiation of epoprostenol. Seven of the remaining eight patients had a persistent clinical improvement. Short-term epoprostenol therapy is effective in some patients with connective tissue diseases as demonstrated by better clinical status and haemodynamics at six weeks. However, this study reports several cases of early and late major complications including severe sepsis and pulmonary oedema. Additional information is needed to evaluate the benefit: risk ratio of long-term epoprostenol therapy in pulmonary hypertension secondary to connective tissue diseases.

[1]  M. Petri.  Management of thrombosis in antiphospholipid antibody syndrome. , 2001, Rheumatic diseases clinics of North America.

[2]  M. Humbert,et al.  Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.

[3]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[4]  Y. Okano,et al.  Orally active prostacyclin analogue in primary pulmonary hypertension , 1997, The Lancet.

[5]  M Abu-Shakra,et al.  Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. , 1996, British journal of rheumatology.

[6]  G. Simonneau,et al.  Improvement of severe pulmonary hypertension in a patient with SLE. , 1996, Annals of the rheumatic diseases.

[7]  W. Seeger,et al.  Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension , 1996, Annals of Internal Medicine.

[8]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[9]  A. Denjean,et al.  Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.

[10]  J. Gómez-Reino,et al.  Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. , 1994, Arthritis and rheumatism.

[11]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.

[12]  B. Munt,et al.  Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. , 1992, The Journal of rheumatology.

[13]  G. Hughes,et al.  Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. , 1990, The Journal of rheumatology.

[14]  S. Yousem.  The pulmonary pathologic manifestations of the CREST syndrome. , 1990, Human pathology.

[15]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[16]  J. Kirby,et al.  Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. , 1989, BMJ.

[17]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[18]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[19]  T. Medsger,et al.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.

[20]  T. Higenbottam,et al.  LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) , 1984, The Lancet.

[21]  D. Furst,et al.  Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. , 1983, The American journal of medicine.

[22]  B. Groves,et al.  Prostacyclin‐induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension , 1982, Circulation.

[23]  J. Shaver,et al.  Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). , 1977, Annals of internal medicine.

[24]  P. Lambert,et al.  [Immunosuppressive therapy]. , 1974, Ergebnisse der inneren Medizin und Kinderheilkunde.

[25]  R. Naeye.  PULMONARY VASCULAR LESIONS IN SYSTEMIC SCLERODERMA. , 1963, Diseases of the chest.